CAL-101: Additional Phase I data

Additional data from 99 evaluable patients in both the dose-escalation and expansion stages of an ongoing, open-label, U.S. Phase I trial showed that oral CAL-101 produced overall response rates (ORR) of 57%, 67% and 30% in patients with indolent non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), respectively. Additionally, CAL-101 produced 13 partial responses (PR) and 4 cases of stable disease (SD) in 23 evaluable indolent NHL patients; 8 PRs and 1 case of SD in 12 evaluable MCL patients; and 10 PRs and 11 cases of SD in 33 evaluable CLL patients. CAL-101 was well tolerated with a low incidence of hematological toxicity. ...